Navigation Links
Henry Ford Hospital study: Fewer infections with new heart-pump implant
Date:5/27/2010

A state-of-the-art heart pump recently approved for use in end-stage cardiac patients has a significantly lower risk for infection than an earlier model of the device, according to researchers at Henry Ford Hospital in Detroit.

Known as a left ventricular assist device, the newest version of the HeartMate is much smaller than the first and uses a tiny turbine with synthetic ruby bearings, lubricated by the blood itself, to continually push blood through the body. Its predecessor is larger, heavier, has more moving parts, and is designed to mimic the pulsing of blood through a healthy heart.

Implanting the latest version of the pump is also less invasive, so researchers at the Henry Ford Heart & Vascular Institute sought to find whether it offered less risk of infection.

"Left ventricular assist devices have become the standard of care for patients with end-stage heart failure," says lead author Jeffrey A. Morgan, M.D. Associate Director of Circulatory Assist Device Program and Cardiac Transplantation, at Henry Ford. "However, development of a device-related infection can be a source of significant morbidity and mortality.

"The HeartMate II was designed to address specific limitations of the HM I, including minimizing the invasiveness of LVAD implantation. The focus of this study was to ascertain whether the HeartMate II was associated with a decreased incidence of device-related infections."

The study will be presented May 27 at the American Society for Artificial Internal Organs in Baltimore.

The study, which ran from March 2006 through June 2009, included 58 patients with chronic heart failure who were implanted with either the HeartMate II which the U.S. Food and Drug Administration approved in January for use in patients with severe heart failure who are not candidates for a heart transplant or its predecessor, the larger and more complicated HeartMate I XVE.

.

Of the study group, 41 patients were implanted with the HeartMate II and 17 with the older model. Those who developed infections were treated with antibiotics, and the effects of those infections on their short- and long-term survival were also studied.

Two patients, or 4.9 percent of those who had HeartMate II pumps, developed infections, compared to four patients, or 23.5 percent of those whose hearts were assisted by the previous model. The researchers also found no significant difference in survival between HM II patients with and without infection at 30 days and one year.


'/>"/>

Contact: Dwight Angell
dwight.angell@hfhs.org
313-876-8709
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Henry Ford Hospital: New left-side heart pump improves right-side heart function
2. Henry Ford Hospital study: Less prep needed for colonoscopy
3. Henry Ford Health System goes radical: Creating the hospital of the future
4. Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer
5. Henry Ford Hospital study: Shoulder function not fully restored after surgery
6. Henry Ford Hospital study shows link between vitamin D, skin cancer
7. Alan Henry, M.D. Joins MedSolutions as Chief Medical Officer of Premerus
8. National Press Club to Host NEWSMAKER Media Briefing on Cornhusker Kickback With South Carolina Attorney General Henry McMaster
9. iCIMS Emerges as Talent Management Solution of Choice for Henry Ford Health Systems
10. Health Care Pioneer Henry J. Kaiser Inducted Into The California Hall of Fame
11. Proton Therapy Carries Precise, Potent Punch Against Cancers for Patients at The Children's Hospital of Philadelphia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company ... NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic ... organizations that have excellent programs for the delivery and improvement of disease management ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The American ... 2017 marks the 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management ... who have contributed not only to the association, but also to the Health Care ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... On Wednesday, March 22, ... at 5,821.64, up 0.48%; the Dow Jones Industrial ... and the S&P 500 closed at 2,348.45, slightly ... out of nine sectors ended the day in ... on the following Medical Instruments & Supplies equities: ...
(Date:3/23/2017)... 2017 Piramal Pharma ... gibt die Ernennung von Stuart E. Needleman ... globalen Pharmazeutikkunden eine einmalige integrierte End-to-End-Serviceplattform an ... für das erfolgreiche Wachstum und die Umsetzung ... Herr Needleman dafür verantwortlich sein, alle globalen ...
(Date:3/23/2017)... 23, 2017 Merrimack Pharmaceuticals, Inc. (NASDAQ: ... patient in a Phase 1 study of MM-310 in ... encapsulates a novel taxane and targets the EphA2 receptor, ... of many major tumor types, including prostate, ovarian, bladder, ... of this study is an important step in evaluating ...
Breaking Medicine Technology: